Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory, Autoimmune, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-6 drug discovery.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-6 Recombinant Protein (HEK293 expressed, >95% purity, <1 EU/ug, mass spec verified) | View IL-6 Products |
| Gene Delivery | IL-6 Promise-ORF / Lentivirus (full-length ORF for stable cell lines) | View IL-6 Products |
| Benchmark Ab | Anti-IL-6 (sequence of Siltuximab) and Anti-IL-6R (sequence of Tocilizumab biosimilar) recombinant positive controls | View IL-6 Products |
| Validator | IL-6 siRNA Set (3 pre-designed sequences, >80% knockdown) | View IL-6 Products |
| Related Target IL-6R | IL-6R (CD126) ECD-Fc; for receptor occupancy and classical signaling assays | View IL-6R Products |
| Related Target gp130 | gp130/IL6ST ECD-Fc; signal-transducing co-receptor for ternary complex SPR | View gp130 Products |
| Related Target LIF | LIF (Leukemia Inhibitory Factor); IL-6 family member for off-target screening | View LIF Products |
| Related Target OSM | OSM (Oncostatin M); IL-6 family member for cross-reactivity validation | View OSM Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage |
|---|---|
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno IL-6 orthologs available >95% purity |
| gp130 family counter-screening | Homolog panel (IL-11, LIF, OSM) verified by mass spec |
| Ternary complex assembly (IL-6/IL-6R/gp130) | IL-6R ECD-Fc & gp130 ECD-Fc for SPR/BLI; native glycosylation (HEK293) |
| Classical vs trans-signaling discrimination | Soluble IL-6R (sIL-6R) and membrane-bound ECD variants available separately |
| Neutralization potency standardization | Clinical benchmark antibodies (Siltuximab, Tocilizumab biosimilar sequences) as reference controls |
| Specificity verification | Validated siRNA included for target-specificity checks in cellular assays |
Live IL-6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-6 therapeutics is intensifying. Major players are shifting focus from traditional monoclonal antibodies (Siltuximab, Tocilizumab, Sarilumab) to next-generation modalities including recycling antibodies (e.g., Satralizumab), bispecifics, and trans-signaling selective inhibitors (e.g., Olamkicept, a gp130-Fc fusion). As first-generation therapies face biosimilar competition, the next wave of R&D targets tumor microenvironment modulation, combination immunotherapy, and optimized subcutaneous delivery with extended half-life. A key differentiator is the ability to selectively block IL-6 trans-signaling while preserving classical signaling, potentially reducing infection-related adverse events without compromising efficacy in oncology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Anti-IL-6 mAb | EUSA Pharma, Johnson & Johnson | Castleman Disease, Multiple Myeloma | Neutralization assay (high-purity IL-6 antigen + TF-1 cell validation) |
| Anti-IL-6R mAb | Roche, Sanofi/Regeneron | Rheumatoid Arthritis, CRS, GCA | Receptor competition assays (IL-6R ECD-Fc + gp130 trimeric complex) |
| Recycling Antibody | Chugai, Roche (Satralizumab) | Neuromyelitis Optica | pH-dependent SPR binding (highly stable antigens) |
| Bispecific / Cytokine Trap | Various biotechs | Solid Tumors, Autoimmune | Heterodimer validation (cross-reactive Abs, dual-target proteins) |
| Biosimilars (emerging) | Bio-Thera, Mabpharm | Autoimmune disorders | Bioanalytical equivalence (clinical reference antibodies + calibrator proteins) |
Molecular Differentiation & Screening Assay Strategies
Given the complexity of IL-6 signaling — classical (via membrane IL-6R) and trans-signaling (via soluble IL-6R) — therapeutic candidates must be carefully profiled. Key screening assays include:
- Signal selectivity assay: Use Ba/F3 cells expressing either mIL-6R+gp130 (classical) or gp130 only + sIL-6R (trans) to assess selectivity.
- Family cross-reactivity panel: SPR against LIF, OSM, IL-11, CNTF to confirm specificity.
- Neutralization potency: TF-1 cell proliferation inhibition or STAT3 phosphorylation ELISA, with Siltuximab/Tocilizumab as controls.
- Ternary complex disruption: Competitive SPR using pre-formed IL-6/sIL-6R complex against gp130.
- Specificity verification: IL-6 siRNA knockdown rescue experiments.
TarMart supports all these assays with high-quality proteins (human/mouse/cyno IL-6, IL-6R, gp130, sIL-6R, LIF, OSM, IL-11), benchmark antibodies (Siltuximab and Tocilizumab biosimilar sequences), and validated siRNA.